These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 22467260)

  • 1. Role of antithrombotic agents in heart failure.
    Cleland JG; Mumtaz S; Cecchini L
    Curr Cardiol Rep; 2012 Jun; 14(3):314-25. PubMed ID: 22467260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic therapy for heart failure in sinus rhythm.
    Subramaniam V; Davis RC; Shantsila E; Lip GY
    Fundam Clin Pharmacol; 2009 Dec; 23(6):705-17. PubMed ID: 19735305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
    Yuan C; Zhong L; Huang RC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jun; 45(6):526-535. PubMed ID: 28648031
    [No Abstract]   [Full Text] [Related]  

  • 4. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
    Thompson PL; Verheugt FW
    Clin Ther; 2014 Sep; 36(9):1176-81. PubMed ID: 25234549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives.
    Gurbel PA; Tantry US
    JACC Heart Fail; 2014 Feb; 2(1):1-14. PubMed ID: 24622113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure in sinus rhythm: no routine antithrombotic therapy.
    Prescrire Int; 2015 Jan; 24(156):25. PubMed ID: 25729838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome].
    Tubaro M; Falaschi G; Colivicchi F
    G Ital Cardiol (Rome); 2018 Oct; 19(10):552-562. PubMed ID: 30281043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotics in atrial fibrillation and coronary disease.
    Velagapudi P; Turagam MK; Agrawal H; Mittal M; Kocheril AG; Aggarwal K
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):977-86. PubMed ID: 25046150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic therapy for atrial fibrillation.
    Lip GY; Hart RG; Conway DS
    BMJ; 2002 Nov; 325(7371):1022-5. PubMed ID: 12411366
    [No Abstract]   [Full Text] [Related]  

  • 10. The Role of Antithrombotic Therapy in Heart Failure.
    Chrysohoou C; Magkas N; Antoniou CK; Manolakou P; Laina A; Tousoulis D
    Curr Pharm Des; 2020; 26(23):2735-2761. PubMed ID: 32473621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents.
    Paikin JS; Mehta SR; Eikelboom JW
    Med J Aust; 2010 May; 192(9):487-8. PubMed ID: 20438416
    [No Abstract]   [Full Text] [Related]  

  • 12. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals.
    Albers GW; Yim JM; Belew KM; Bittar N; Hattemer CR; Phillips BG; Kemp S; Hall EA; Morton DJ; Vlasses PH
    Arch Intern Med; 1996 Nov; 156(20):2311-6. PubMed ID: 8911237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials.
    Andò G; Costa F
    Int J Cardiol; 2020 Mar; 302():95-102. PubMed ID: 31924397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Camaj A; Miller MS; Halperin JL; Giustino G
    Cardiol Clin; 2020 Nov; 38(4):551-561. PubMed ID: 33036717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Atrial fibrillation and thromboembolic events prevention. State of the art].
    Matteoli S; Trappolini M; Chillotti FM
    Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
    Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative].
    Själander A; Wallentin L; Rosenqvist M; Svensson P
    Lakartidningen; 2008 Sep 10-16; 105(37):2478-80. PubMed ID: 19006862
    [No Abstract]   [Full Text] [Related]  

  • 20. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
    Lip GY; Piotrponikowski P; Andreotti F; Anker SD; Filippatos G; Homma S; Morais J; Pullicino P; Rasmussen LH; Marín F; Lane DA;
    Thromb Haemost; 2012 Dec; 108(6):1009-22. PubMed ID: 23093044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.